{"product_id":"yi-vrio-analysis","title":"111, Inc. (YI): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to 111, Inc. (YI)'s market dominance (or potential pitfalls) starts here: this VRIO analysis strips down its core assets to reveal if its Value, Rarity, Inimitability, and Organization truly forge a sustainable competitive advantage. Scroll down now to see the distilled truth about what makes 111, Inc. (YI) powerful - or vulnerable - in the landscape.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003e111, Inc. (YI) - VRIO Analysis: 1. Largest Virtual Pharmacy Network in China (B2B Reach)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at 111, Inc.'s core moat, and it’s built on sheer physical scale, which is rare in a digitally-focused world. This network is the backbone of their B2B strategy, connecting them directly to the last mile of healthcare delivery in China. The key takeaway here is that this scale is a massive barrier to entry for competitors trying to replicate their distribution efficiency.\u003c\/p\u003e\n\n\u003cp\u003eThe value proposition is clear: 111, Inc. empowers offline pharmacies to operate more efficiently, acting as their digital wholesaler and service provider. As of the first quarter of 2025, this virtual network served approximately \u003cstrong\u003e0.58 million\u003c\/strong\u003e pharmacies nationwide. This massive reach is what drives their B2B segment, which is the primary revenue engine for the firm, even as the overall company navigated a challenging macroeconomic environment with Q1 2025 net revenues stable at \u003cstrong\u003eRMB 3.5 billion\u003c\/strong\u003e (US$486.3 million).\u003c\/p\u003e\n\n\u003cp\u003eRarity is a definite yes. Building a trusted, integrated network of this magnitude - one that handles pharmaceutical logistics - takes years of on-the-ground work and navigating complex regulatory hurdles in China. Imitability is therefore high; it’s not just about capital, it’s about time and established trust. Organizationally, 111, Inc. has structured its operations to exploit this asset, using its national logistics network, 'Penglai,' to provide efficient distribution services to these partners.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the assessment:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n    \u003ctd\u003eAssessment\u003c\/td\u003e\n    \u003ctd\u003eCompetitive Implication\u003c\/td\u003e\n    \u003ctd\u003eScore\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eYes, enables majority revenue driver (B2B)\u003c\/td\u003e\n    \u003ctd\u003eCompetitive Parity to Advantage\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eYes, largest virtual network in China\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eDifficult; requires years of partnership building and regulatory navigation\u003c\/td\u003e\n    \u003ctd\u003ePotential Sustained Advantage\u003c\/td\u003e\n    \u003ctd\u003eDifficult\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eHigh; clearly structured B2B segment leverages network\u003c\/td\u003e\n    \u003ctd\u003eSustained Competitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the pressure on margins; while the network is strong, Q1 2025 saw gross segment profit decrease by \u003cstrong\u003e6.4%\u003c\/strong\u003e year-over-year. Still, the underlying asset remains powerful.\u003c\/p\u003e\n\n\u003cp\u003eTo truly capitalize on this, you need to focus on deepening the integration:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eExpand fulfillment centers; the plan was to add at least \u003cstrong\u003e14\u003c\/strong\u003e more by the end of 2025.\u003c\/li\u003e\n\u003cli\u003eDeepen strategic direct procurement partnerships, currently over \u003cstrong\u003e500\u003c\/strong\u003e pharmaceutical companies.\u003c\/li\u003e\n\u003cli\u003eLeverage the network for higher-margin digital services like telemedicine.\u003c\/li\u003e\n\u003cli\u003eMaintain operational efficiency; total operating expenses as a percentage of revenue improved by \u003cstrong\u003e30 basis points\u003c\/strong\u003e year-over-year in Q1 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003e111, Inc. (YI) - VRIO Analysis: 2. Integrated Online and Offline Platform Structure\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Creates an omni-channel experience, capturing both direct consumer sales (B2C) and pharmacy sourcing (B2B).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate; competitors have online or offline, but a deep, functional integration is less common.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Difficult; replicating the seamless flow between 1 Pharmacy, 1 Drug Mall, and the offline network is complex.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: High; the entire business model is built around this integration, as seen by their consistent revenue base.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary; while strong now, a major competitor could potentially build a similar bridge with massive investment.\u003c\/p\u003e\n\u003cp\u003eThe integrated structure supports the overall financial performance, evidenced by the shift to operating profitability.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eB2B Segment (Sourcing\/Wholesale)\u003c\/td\u003e\n\u003ctd\u003eB2C Segment (Direct-to-Consumer)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenue (Q4 2024, in thousands RMB)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4,020,817\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e87,809\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSegment Profit % (Q4 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Net Revenue (FY 2024, in RMB)\u003c\/td\u003e\n\u003ctd colspan=\"2\"\u003e\u003cstrong\u003e14.40 Billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Net Revenue (FY 2023, in USD)\u003c\/td\u003e\n\u003ctd colspan=\"2\"\u003e\u003cstrong\u003e$2.11 Billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe scale and efficiency derived from this integration are quantified by network size and logistics performance:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVirtual pharmacy network serves approximately \u003cstrong\u003e470,000\u003c\/strong\u003e pharmacies.\u003c\/li\u003e\n\u003cli\u003ePartnerships include over \u003cstrong\u003e500\u003c\/strong\u003e global pharmaceutical companies and \u003cstrong\u003e4,500\u003c\/strong\u003e distributors.\u003c\/li\u003e\n\u003cli\u003eTotal fulfillment centers across China: \u003cstrong\u003e13\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe 'Kunpeng' logistics network achieved a \u003cstrong\u003e15%\u003c\/strong\u003e reduction in delivery costs and a \u003cstrong\u003e55%\u003c\/strong\u003e reduction in damage rates.\u003c\/li\u003e\n\u003cli\u003eAI algorithms are utilized to improve pharmaceutical qualification review efficiency by over \u003cstrong\u003e100%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eOrganizational alignment is reflected in the financial turnaround:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFY 2024 GAAP operating income: \u003cstrong\u003eRMB 2.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFY 2023 GAAP operating loss: \u003cstrong\u003eRMB 350.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFY 2024 cash flow from operations: \u003cstrong\u003eRMB 263 million\u003c\/strong\u003e (positive).\u003c\/li\u003e\n\u003cli\u003eOperating expenses as a percentage of net revenues decreased to \u003cstrong\u003e5.7%\u003c\/strong\u003e in FY 2024 from \u003cstrong\u003e8.0%\u003c\/strong\u003e in FY 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe competitive advantage is tempered by thin margins:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGross margins remained thin at approximately \u003cstrong\u003e5–6%\u003c\/strong\u003e in 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003e111, Inc. (YI) - VRIO Analysis: 3. Operational Efficiency and Cost Discipline\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Translates directly into profitability, evidenced by maintaining quarterly operational profitability through \u003cstrong\u003eQ2 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenues\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRMB3.5 billion\u003c\/strong\u003e (US$486.3 million)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRMB3.2 billion\u003c\/strong\u003e (US$447.5 million)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIncome from Operations\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eRMB0.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRMB0.1 million\u003c\/strong\u003e (US$0.01 million)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-GAAP Income from Operations\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRMB4.3 million\u003c\/strong\u003e (US$0.6 million)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRMB3.0 million\u003c\/strong\u003e (US$0.4 million)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Expenses as % of Net Revenues\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5.5%\u003c\/strong\u003e (30 bps decrease YoY)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5.8%\u003c\/strong\u003e (20 bps decrease YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash from Operating Activities\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRMB112.6 million\u003c\/strong\u003e (US$15.5 million)\u003c\/td\u003e\n\u003ctd\u003ePositive in the First Half of the Year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes; achieving consistent profitability while growing in this low-margin B2B space is rare.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; competitors can copy processes, but achieving best-in-class operator status requires deep, embedded tech.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; management explicitly focuses on efficiency, as shown by operating expense control in \u003cstrong\u003eQ1 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal operating expenses in Q1 2025 were \u003cstrong\u003eRMB195.0 million\u003c\/strong\u003e (US$26.9 million), a decrease of \u003cstrong\u003e4.8%\u003c\/strong\u003e Year-over-Year (YoY).\u003c\/li\u003e\n\u003cli\u003eSelling and marketing expenses saw a reduction of \u003cstrong\u003e15.5%\u003c\/strong\u003e in Q1 2025 compared to the prior year.\u003c\/li\u003e\n\u003cli\u003eTechnology expenses decreased by \u003cstrong\u003e15.6%\u003c\/strong\u003e in Q1 2025 compared to the prior year.\u003c\/li\u003e\n\u003cli\u003eTotal operating expenses as a percentage of net revenues improved to \u003cstrong\u003e5.5%\u003c\/strong\u003e in Q1 2025, a decrease of \u003cstrong\u003e30 basis points\u003c\/strong\u003e from the same period last year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; this efficiency is a core differentiator against online B2B rivals.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003e111, Inc. (YI) - VRIO Analysis: 4. Smart Supply Chain Integration\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Modernizes product flow from manufacturers to pharmacies, reducing friction and likely lowering landed costs.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; while others have supply chains, 111, Inc.'s integration of front and back ends is a specific capability.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; this requires proprietary logistics technology and deep integration with upstream partners.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this capability underpins their B2B value proposition and efficiency gains.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; technology-driven supply chain expertise is a key differentiator.\u003c\/p\u003e\n\u003cp\u003eThe smart supply chain capability is demonstrated through measurable improvements in operational cost structure and delivery speed:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFulfillment expenses were RMB381.0 million ($52.2 million) in 2024, representing a decrease of 4.9% from RMB400.5 million in 2023.\u003c\/li\u003e\n\u003cli\u003eFulfillment expenses as a percentage of net revenues were 2.6% in 2024, compared to 2.7% in 2023.\u003c\/li\u003e\n\u003cli\u003eIn Q2 2024, fulfillment expenses as a percentage of net revenues were 2.6%, down from 2.7% in the same quarter last year, reflecting a decrease in fulfillment costs by 7.3%.\u003c\/li\u003e\n\u003cli\u003eTotal operating expenses as a percentage of net revenues decreased by 470 basis points to 5.5% in Q4 2024 from 10.2% in Q4 2023.\u003c\/li\u003e\n\u003cli\u003eThe company is positioned to deliver to over 300 major cities nationwide within 24 hours and cover the entire nation within 72 hours.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFulfillment Expenses YoY Change\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-4.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024 vs 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFulfillment Expenses as % of Net Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Operating Expenses as % of Net Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDelivery Coverage (24 Hours)\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e300\u003c\/strong\u003e major cities\u003c\/td\u003e\n\u003ctd\u003eNationwide capability\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies Served (Virtual Network)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e470,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eIndirect network size\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe organizational structure supports this integration, evidenced by:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAchieving first-ever annual operating profit in 2024.\u003c\/li\u003e\n\u003cli\u003eReporting income from operations of RMB 3.3 million in Q2 2024, compared to a loss from operations of RMB 41.4 million a year ago.\u003c\/li\u003e\n\u003cli\u003eNon-GAAP income from operations was RMB 22.3 million ($3.0 million) in 2024, compared to a non-GAAP loss from operations of RMB 123.9 million in 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003e111, Inc. (YI) - VRIO Analysis: 5. Drug Commercialization Support Services\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides high-margin, value-added services (digital marketing, data analytics) to strategic pharmaceutical partners.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eHistorical service revenues reached \u003cstrong\u003eRMB 324.5 million (US$49.0 million)\u003c\/strong\u003e in the first half of 2018.\u003c\/li\u003e\n\u003cli\u003ePharmaceutical logistics and distribution services have helped clients \u003cstrong\u003ereduce costs by 15%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; while marketing exists, offering a full suite of data-driven, omni-channel support is specialized.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company has established partnerships with over \u003cstrong\u003e400 pharmaceutical companies\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; this requires proprietary data sets and established relationships with pharma firms.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company has acquired \u003cstrong\u003e28 patents\u003c\/strong\u003e, with a focus on AI technology applications.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; these services are explicitly offered to partners, showing a clear monetization strategy.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ1 2025 Adjusted Operating Profit was \u003cstrong\u003eRMB 4.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; a large competitor with deep pharma ties could build this out, but it takes time.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Date\u003c\/td\u003e\n\u003ctd\u003eAmount (CNY\/RMB)\u003c\/td\u003e\n\u003ctd\u003eAmount (USD)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Net Revenues\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenues\u003c\/td\u003e\n\u003ctd\u003eFY 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14.9 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUS$2.1 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Segment Profit\u003c\/td\u003e\n\u003ctd\u003eFY 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e849.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUS$119.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Expenses as % of Revenues\u003c\/td\u003e\n\u003ctd\u003eFY 2024\u003c\/td\u003e\n\u003ctd\u003eDecreased \u003cstrong\u003e230 Basis Points\u003c\/strong\u003e YoY\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Income\u003c\/td\u003e\n\u003ctd\u003eQ2 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003e111, Inc. (YI) - VRIO Analysis: 6. Online Healthcare Services (1 Clinic)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Captures consumer demand for convenient online consultation and electronic prescriptions, linking directly to product fulfillment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; telemedicine is growing, but the integration with a massive pharmacy network is unique.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; regulatory hurdles and the need for a large network of affiliated doctors make replication slow.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; it's a growing part of the platform, supporting the B2C side.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; the combination of e-prescription and fulfillment creates a sticky consumer loop.\u003c\/p\u003e\n\u003cp\u003eThe online healthcare services, primarily through 1 Clinic, are supported by the company's extensive infrastructure:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe nationwide virtual pharmacy network serves approximately \u003cstrong\u003e470,000 pharmacies\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe platform provides online consultation and electronic prescription services.\u003c\/li\u003e\n\u003cli\u003eTechnology expenses in Fiscal Year 2023 were \u003cstrong\u003eRMB124.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFulfillment expenses in Fiscal Year 2023 were \u003cstrong\u003eRMB400.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSelected financial metrics illustrating the scale of the integrated platform supporting the online services:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eFiscal Year 2024\u003c\/td\u003e\n\u003ctd\u003eFiscal Year 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenues\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRMB14.4 billion\u003c\/strong\u003e (US$2.0 billion)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRMB14.9 billion\u003c\/strong\u003e (US$2.1 billion)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss Attributable to Ordinary Shareholders\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRMB64.7 million\u003c\/strong\u003e (US$8.9 million)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eRMB392.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ4 Net Revenues\u003c\/td\u003e\n\u003ctd\u003eData not explicitly available for Q4 2024 in search results\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRMB4.1 billion\u003c\/strong\u003e (US$578.7 million)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003e111, Inc. (YI) - VRIO Analysis: 7. Financial Resilience and Profitability Track Record\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows the company to invest for the long term and weather macroeconomic storms, as seen by maintaining positive operating cash flow in the first half of 2025.\u003c\/p\u003e\n\u003cp\u003eThe company achieved net cash from operating activities of \u003cstrong\u003eRMB112.6 million\u003c\/strong\u003e (US$15.5 million) in the first quarter ended March 31, 2025. The second quarter report confirmed maintaining positive operating cash flow in the first half of the year.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ1 2025 (Ended Mar 31)\u003c\/th\u003e\n\u003cth\u003eQ2 2025 (Ended Jun 30)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenues\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRMB3.5 billion\u003c\/strong\u003e (US$486.3 million)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRMB3.2 billion\u003c\/strong\u003e (US$447.5 million)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Operating Expenses\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRMB195.0 million\u003c\/strong\u003e (US$26.9 million)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRMB185.3 million\u003c\/strong\u003e (US$25.9 million)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Expenses as % of Net Revenues\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5.5%\u003c\/strong\u003e (30 basis points decrease YoY)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5.8%\u003c\/strong\u003e (20 basis points decrease YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIncome from Operations\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRMB0.1 million\u003c\/strong\u003e (US$0.02 million)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRMB0.1 million\u003c\/strong\u003e (US$0.01 million)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-GAAP Income from Operations\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRMB4.3 million\u003c\/strong\u003e (US$0.6 million)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRMB3.0 million\u003c\/strong\u003e (US$0.4 million)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; achieving operational profitability in the current market is a significant achievement.\u003c\/p\u003e\n\u003cp\u003eThe company reported the following profitability metrics for the trailing twelve months ending June 30, 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRevenue: \u003cstrong\u003e$1.98 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eLosses: \u003cstrong\u003e-$10.35 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eLoss per share: \u003cstrong\u003e-$1.20\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTTM Net Profit Margin: \u003cstrong\u003e-0.45%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor Q1 2025, Non-GAAP income from operations was \u003cstrong\u003eRMB4.3 million\u003c\/strong\u003e (US$0.6 million).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; past financial performance is unique to the company's specific cost structure and execution.\u003c\/p\u003e\n\u003cp\u003eSpecific expense reductions contributing to operational efficiency include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSelling and marketing expenses decreased by \u003cstrong\u003e15.5%\u003c\/strong\u003e in Q1 2025 YoY.\u003c\/li\u003e\n\u003cli\u003eTechnology expenses decreased by \u003cstrong\u003e15.6%\u003c\/strong\u003e in Q1 2025 YoY.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; management's stated focus is on maintaining this profitability.\u003c\/p\u003e\n\u003cp\u003eManagement commentary emphasizes continuous improvement in operational efficiency. The company held cash and cash equivalents, restricted cash, and short-term investments totaling \u003cstrong\u003eRMB513.1 million\u003c\/strong\u003e (US$71.6 million) as of June 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; a history of profitability builds investor and partner confidence that is hard to buy.\u003c\/p\u003e\n\u003cp\u003eThe company reported an increase in earnings from \u003cstrong\u003e-$46.9 Million USD\u003c\/strong\u003e in 2023 to \u003cstrong\u003e$1.08 Million USD\u003c\/strong\u003e in 2024.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003e111, Inc. (YI) - VRIO Analysis: 8. Management Team's Technology and Retail Background\n\u003c\/h2\u003e\n\n\u003cp\u003eThe foundation of 111, Inc.'s tech-first strategy is directly attributable to the prior executive experience of its co-founders within global technology and e-commerce giants.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eExecutive\u003c\/th\u003e\n\u003cth\u003ePrior Role\u003c\/th\u003e\n\u003cth\u003eCompany\u003c\/th\u003e\n\u003cth\u003eYears\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDr. Gang Yu\u003c\/td\u003e\n\u003ctd\u003eVP of Worldwide Supply Chain\u003c\/td\u003e\n\u003ctd\u003eAmazon.com\u003c\/td\u003e\n\u003ctd\u003e2004 to 2006\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDr. Gang Yu\u003c\/td\u003e\n\u003ctd\u003eVP of Worldwide Procurement\u003c\/td\u003e\n\u003ctd\u003eDell Inc.\u003c\/td\u003e\n\u003ctd\u003e2006 to 2007\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMr. Junling Liu\u003c\/td\u003e\n\u003ctd\u003eGlobal VP and President for Mainland China and Hong Kong\u003c\/td\u003e\n\u003ctd\u003eDell Inc.\u003c\/td\u003e\n\u003ctd\u003e2006 to 2007\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe founders' prior experience informs the company's tech-first approach to healthcare logistics, evidenced by the strategic pivot to the S2B2C model and the integration of the B2B platform (1 Drug Mall) and Internet hospital (1 Clinic) in 2016.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet Revenues (Q1 2025): \u003cstrong\u003eRMB3.5 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOperational Income (Q1 2024): \u003cstrong\u003eRMB3.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNationwide virtual network serving approximately \u003cstrong\u003e470,000\u003c\/strong\u003e pharmacies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate; this specific blend of large-scale tech\/e-commerce expertise is not common in Chinese healthcare platforms.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eLow; the specific experience and vision of the co-founders, including Dr. Yu's background in supply chain and procurement at Amazon and Dell, cannot be easily replicated by hiring.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eHigh; this experience is clearly embedded in the company's strategy to reshape the value chain, supported by infrastructure metrics.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal Fulfillment Centers across China (as of Oct 2024): \u003cstrong\u003e13\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDelivery cost reduction achieved through the 'Kunpeng' logistics network: \u003cstrong\u003e15%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDelivery damage rate reduction: \u003cstrong\u003e55%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Fulltime Employees: \u003cstrong\u003e1238\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary; this advantage fades as the founders eventually transition or new, equally experienced leaders emerge.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003e111, Inc. (YI) - VRIO Analysis: 9. Brand Recognition and Consumer Trust (1 Pharmacy\/1 Drugstore)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Drives consumer adoption for direct-to-consumer sales and builds the base for prescription fulfillment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; established brands in a fragmented market have an edge, but it's not a monopoly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; brand building is slow, but heavy marketing spend can accelerate imitation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; the B2C segment relies on this trust for customer acquisition.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; strong, but vulnerable to aggressive marketing by JD Health or Alibaba Health.\u003c\/p\u003e\n\u003cp\u003eQ1 2025 Net Revenues were reported as \u003cstrong\u003eRMB 3.5 billion\u003c\/strong\u003e (US$486.3 million).\u003c\/p\u003e\n\u003cp\u003eQ1 2025 B2C Net Revenue (Product and Service) was \u003cstrong\u003eRMB 55.041 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eQ1 2025 Total Cost of Products Sold was \u003cstrong\u003eRMB 3.33 billion\u003c\/strong\u003e (US$459.5 million).\u003c\/p\u003e\n\u003cp\u003eBased on the Q1 2025 reported figures, the estimated B2B\/B2C revenue split for the RMB 3.5 billion base is:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eSegment\u003c\/td\u003e\n\u003ctd\u003eEstimated Q1 2025 Revenue (RMB Million)\u003c\/td\u003e\n\u003ctd\u003eEstimated Share of Total Revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eB2B\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3,473.96\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e98.44%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eB2C\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e55.04\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.56%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Base\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3,529.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100.00%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSensitivity Analysis on RMB 3.5 billion Q1 2025 Revenue for Hypothetical Q3 2025 Scenario:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eBase Q1 2025 Revenue (RMB Million)\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Scenario Change\u003c\/td\u003e\n\u003ctd\u003eProjected Q3 2025 Revenue (RMB Million)\u003c\/td\u003e\n\u003ctd\u003eTotal Revenue Impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eB2B Revenue\u003c\/td\u003e\n\u003ctd\u003e3,445.40\u003c\/td\u003e\n\u003ctd\u003e-5%\u003c\/td\u003e\n\u003ctd\u003e3,273.13\u003c\/td\u003e\n\u003ctd\u003e-4.77%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eB2C Revenue\u003c\/td\u003e\n\u003ctd\u003e54.60\u003c\/td\u003e\n\u003ctd\u003e+10%\u003c\/td\u003e\n\u003ctd\u003e60.06\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e3,500.00\u003c\/td\u003e\n\u003ctd\u003eCombined Effect\u003c\/td\u003e\n\u003ctd\u003e3,333.19\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAdditional relevant operational metrics from Q1 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNon-GAAP income from operations was \u003cstrong\u003eRMB 4.3 million\u003c\/strong\u003e (US$0.6 million).\u003c\/li\u003e\n\u003cli\u003eSelling and marketing expenses were \u003cstrong\u003eRMB 67.9 million\u003c\/strong\u003e (US$9.4 million).\u003c\/li\u003e\n\u003cli\u003eSelling and marketing expenses as a percentage of net revenues decreased by 15.5% year-over-year.\u003c\/li\u003e\n\u003cli\u003eFulfillment expenses accounted for \u003cstrong\u003e2.7%\u003c\/strong\u003e of net revenues.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516285706389,"sku":"yi-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/yi-vrio-analysis.png?v=1740140286","url":"https:\/\/dcf-model.com\/products\/yi-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}